Individual Women, Individual HRT


A combined portfolio of HRT treatment options

Prescribing
Information

ELLESTE™ (estradiol +/- norethisterone acetate)
Prescribing Information

Presentation: Elleste Solo™ 1 mg and 2 mg film-coated tablets containing estradiol hemihydrate 1 mg and 2 mg respectively. Elleste Solo™ MX 40 mcg transdermal patch containing 1.25 mg estradiol hemihydrate and Elleste Solo™ MX 80 mcg Transdermal Patch containing 2.5 mg estradiol hemihydrate and delivers 40 and 80 micrograms of estradiol respectively per 24 hours. Elleste Duet™ 1 mg film-coated tablets containing estradiol hemihydrate 1 mg (white tablets) and estradiol hemihydrate 1 mg and norethisterone acetate 1 mg (pale green tablets). Elleste Duet™ 2 mg film-coated tablets containing estradiol hemihydrate 2 mg (orange tablets) and estradiol hemihydrate 2 mg and norethisterone acetate 1 mg (grey tablets). Elleste Duet™ Conti film-coated tablets containing 2 mg estradiol hemihydrate and 1 mg norethisterone acetate.

Indication: Hormone replacement therapy for oestrogen deficiency symptoms in peri- and post-menopausal women (Elleste Solo™; Elleste Duet™; Elleste Solo™ MX 40 patch) and in post-menopausal women with an intact uterus who are at least one-year post menopause (Elleste Duet™ Conti). Prevention of osteoporosis in post-menopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis (Elleste Duet™ Conti; Elleste Duet™ 2 mg; Elleste Solo™ 2 mg; Elleste Solo™ MX 80 patch).

Dosage and Administration: Elleste Solo™ 1 mg and 2 mg film-coated tablets: One tablet daily in hysterectomised women; in women with an intact uterus, progestogen should be added for 12-14 days each cycle. Elleste Solo™ MX 40 and 80 patch: initiate treatment with Elleste Solo™ MX 40 in women with menopausal symptoms. If menstruating regularly, start within five days of bleeding. See SmPC for details of switching from other forms of HRT. Apply one patch twice weekly; in women with an intact uterus, progestogen should be added for 12-14 days during each cycle. The dosage may be increased by using Elleste Solo™ MX 80. Elleste Duet 1 mg film-coated tablets: One white tablet taken daily for 16 days followed by one pale green tablet taken daily for 12 days, then begin a new cycle without a break. Elleste Duet™ 2 mg film-coated tablets: One orange tablet taken daily for 16 days followed by one grey tablet taken daily for 12 days, then begin a new cycle without a break. Elleste Duet™ Conti: One tablet taken daily.

Contra-indications: Pregnancy or breastfeeding. Known, past or suspected breast cancer. Known or suspected oestrogen dependent malignant tumours. Undiagnosed genital bleeding. Untreated endometrial hyperplasia. Active thrombophlebitis. Previous idiopathic or current venous thromboembolism. Known thrombophilic disorders. Active or recent arterial thromboembolic disease. Acute liver disease or history of liver disease as long as LFTs are abnormal. Dubin-Johnson or Rotor Syndromes. Hypersensitivity to the active substances or excipients. Porphyria.

Warnings and Precautions: HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually. HRT should only be continued as long as the benefit outweighs the risk. Before initiating or reinstituting HRT, take a complete personal and family medical history and perform appropriate physical examinations. Advise women about what breast changes should be reported. Closely supervise women with the following conditions or a history of them: leiomyoma or endometriosis; history of, or risk factors for, thromboembolic disease; risk factors for oestrogen dependent tumours; hypertension; liver disorders; diabetes mellitus; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; endometrial hyperplasia; epilepsy; asthma; otosclerosis. Discontinue therapy if a contraindication is discovered and in the following conditions: hepatitis, jaundice or deteriorating liver function; significant increase in blood pressure; sudden severe chest pain; sudden breathlessness; unexplained swelling or pain in calf; severe stomach pain; prolonged immobility after surgery or leg injury; new onset migraine-type headache; pregnancy. Risk of endometrial hyperplasia and carcinoma are increased when oestrogens are administered alone for prolonged periods. The risk is reduced with the addition of a progestogen for at least 12 days per cycle in non-hysterectomised women. Investigate breakthrough bleeding. An increased risk of breast cancer has been reported that is dependent on the length of treatment. HRT can increase the density of mammographic images which may affect radiological detection of breast cancer. HRT is associated with an increased relative risk of venous thromboembolism (VTE) or pulmonary embolism (PE). Risk factors include personal or family history of thrombosis, severe obesity, systemic lupus erythematosus, immobilisation, major trauma and major surgery. Consider discontinuing HRT 4-6 weeks before elective surgery requiring immobilisation. Therapy should be discontinued if VTE develops after initiating surgery. There is an increased risk of cardiovascular morbidity during the first year of use of HRT. HRT is associated with an up to 1.5-fold increased risk of stroke. Long term use of oestrogens in women has been associated with an increased risk of ovarian cancer. Oestrogens may cause fluid retention. Women with preexisting hypertriglyceridemia should be followed closely (risk of pancreatitis). Certain endocrine tests may be affected. No evidence for improvement in cognitive function. Increased risk of gallbladder disease. Liver tumours leading to intra-abdominal haemorrhage have been reported. Patients with rare hereditary disorders of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Elleste™ Duet 2 mg film-coated tablets and Elleste™ Solo 2 mg film-coated tablets contain sunset yellow colouring (E110) which can cause allergic reactions. May interact with other medicines. See SmPC for potential interactions.

Side Effects: Common side effects (>1/100): Erythema, itching; uterine bleeding; breast tenderness and enlargement; increase in size of uterine fibroids; nausea; abdominal pain; headache; weight increase/decrease; oedema; change in mood including anxiety and depressive mood; change in libido. Other side effects include: Vaginal candidiasis; vomiting; gallbladder disease; pancreatitis, gallstones; dizziness; migraine; increased blood pressure; leg cramps; alopecia; hirsutism; rash; itching; venous thromboembolism; thrombophlebitis; thrombosis; endometrial neoplasia; dysmenorrhoea; aggravation of endometriosis; changes in cervical eversion, production of mucus and erosion; cystitis-like syndrome; endometrial cancer; breast cancer; bloating; myocardial infarction; stroke; liver tumours; cholestatic jaundice; chloasma; erythema multiforme; erythema nodosum; muscle cramps; vascular purpura; steepening of corneal curvature; visual disturbances; intolerance to contact lenses; sodium and water retention; reduced glucose tolerance; aggravation of porphyria and probable dementia. See SmPC for all side effects.

Marketing Authorisation Numbers and Cost: Elleste Solo™ 1mg: PL 46302/0169; 3 x 28 film-coated tablets £5.06. Elleste Solo™ 2mg: PL 46302/0170; 3 x 28 film-coated tablets £5.06. Elleste Solo™ MX 40 mcg: PL 46302/0167; 8 patches £5.19. Elleste Solo™ MX 80 mcg: PL 46302/0168; 8 patches £5.99. Elleste Duet™ 1mg: PL 46302/0164; 3 x 28 film-coated tablets £9.20. Elleste Duet™ 2mg: PL 46302/0165; 3 x 28 film-coated tablets £9.20. Elleste Duet™ Conti: PL 46302/0166; 3 x 28 film-coated tablets £17.02.

Legal Category: POM.

Marketing Authorisation Holder: Mylan Products Ltd. Further information is available on request from: Mylan Products Ltd., Station Close, Potters Bar, Herts, EN6 1LT. Tel. 01707 853000 Date of preparation: October 2018 ELL-2018-0047.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Mylan by phone: 0800 121 8267 or by email: ukpharmacovigilance@mylan.com

PRESCRIBING INFORMATION:
Femoston 1/10 mg film-coated tablets
Femoston 2/10 mg film-coated tablets
Refer to the Summary of Product Characteristics for full information.

Presentation: Femoston 1/10 mg film-coated tablets containing 1 mg oestradiol (as hemihydrate) or a combination of 1 mg oestradiol (as hemihydrate) and 10 mg dydrogesterone. Femoston 2/10 mg film-coated tablets containing 2 mg oestradiol (as hemihydrate) or a combination of 2 mg oestradiol (as hemihydrate) and 10 mg dydrogesterone.

Indication: Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

Dosage and Administration: Given as a continuous sequential HRT without a break. For first 14 days of 28-day cycle, one tablet containing oestradiol taken daily; during the following 14 days one tablet containing oestradiol and dydrogesterone is taken. Can be taken before or after food. For initiation and continuation of treatment of postmenopausal symptoms, use lowest effective dose for shortest duration. Generally start with Femoston 1/10, dosage can be adjusted dependent on clinical response. If complaints linked to oestrogen deficiency are not ameliorated dosage can be increased using Femoston 2/10. Women who are not taking HRT and who are amenorrhoeic, or those who switch from a continuous combined HRT treatment can start on any day. If transferring from a cyclic or continuous sequential HRT regimen, treatment should begin the day following completion of prior regimen. Paediatric population: No relevant indication.

Contraindications, Warnings etc: Contraindications: Known, past or suspected breast cancer, known or suspected oestrogen-dependent malignant tumours, known or suspected progestogen-dependent neoplasms, undiagnosed genital bleeding, untreated endometrial hyperplasia, venous thromboembolism, known thrombophilic disorders, arterial thromboembolic disease, acute liver disease or a history of liver disease, porphyria, known hypersensitivity to the active substances or to any of the excipients.
Warnings: Before initiating or re-instituting HRT, a complete physical and family medical history should be taken. Carefully supervise if leiomyoma or endometriosis, risk factors for thromboembolic disorders or oestrogen-dependent tumours, hypertension, liver disorders, diabetes mellitus, cholelithiasis, migraine or severe headaches, systemic lupus erythematosus, history of endometrial hyperplasia, epilepsy, asthma and otosclerosis conditions are present or have previously occurred. Therapy should be discontinued in case a contraindication is discovered; breast cancer, endometrial hyperplasia and carcinoma, ovarian cancer, venous thromboembolism, coronary artery disease, ischaemic stroke, renal dysfunction, hypertriglyceridaemia and in the following situations: jaundice or deterioration in liver function, significant increase in blood pressure, new onset of migraine-type headache, pregnancy. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Oestrogen-progestogen combination treatment is not a contraceptive. Drug Interactions: The metabolism of oestrogens and progestogens may be increased by concomitant use of P450 enzymes such as anticonvulsants and anti-infectives. Ritonavir, nelfinavir and herbal preparations containing St. John’s Wort may induce the metabolism of oestrogens and progestogens. Clinically, an increased metabolism of oestrogens and progestogens may lead to decreased effect and changes in the uterine bleeding profile. Oestrogens may inhibit CYP450 drug-metabolising enzymes via competitive inhibition particularly substances such as tacrolimus and cyclosporine A, fentanyl and theophylline. This may lead to an increased plasma level of the affected substances up to toxic levels. Careful drug monitoring might be indicated and a dosage decrease of tacrolimus, fentanyl, cyclosporine A and theophylline may be necessary.

Pregnancy and Lactation: Not recommended. If pregnancy occurs withdraw treatment immediately.

Ability to Drive and Operate Machinery: No influence on the ability to drive and/or to use machines.

Side Effects: Very Common: Headache, abdominal pain, back pain, breast pain/tenderness. Common: Vaginal candidiasis, depression, nervousness, migraine, dizziness, nausea, vomiting, flatulence, allergic skin reactions (e.g. rash, urticaria, pruritus), menstrual disorders (including postmenopausal spotting, metrorrhagia, menorrhagia, oligo-/amenorrhoea, irregular menstruation, dysmenorrhoea), pelvic pain, cervical discharge, asthenic conditions (asthenia, fatigue, malaise), peripheral oedema, increased weight. Uncommon: Cystitis-like syndrome, increase in size of leiomyoma, hypersensitivity, influence on libido, venous thromboembolism, hypertension, peripheral vascular disease, varicose vein, dyspepsia, abnormal hepatic function, occasionally with jaundice, asthenia or malaise, and abdominal pain, gall bladder disorder, breast enlargement, premenstrual syndrome, decreased weight. Rare: Myocardial infarction, angioedema, vascular purpura. Possible risk factors: Breast cancer, ovarian and endometrial cancer, venous thromboembolism, coronary artery disease and ischaemic stroke. Other adverse reactions: Oestrogen dependent neoplasms both benign and malignant, e.g. endometrial cancer, ovarian cancer, increase in size of progestogen dependent neoplasms, e.g. meningioma, haemolytic anaemia, systemic lupus erythematosus, hypertriglyceridemia, probable dementia over the age of 65, chorea, exacerbation of epilepsy, steepening of corneal curvature, contact lenses intolerance, arterial thromboembolism, pancreatitis (in women with pre-existing hypertriglyceridemia), erythema multiforme, erythema nodosum, chloasma or melasma, which may persist when drug is discontinued, leg cramps, urinary incontinence, fibrocystic breast disease, uterine cervical erosion, aggravated porphyria, total thyroid hormones increased.

Name and Address of Marketing Authorisation Holder: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, UK.


PL No: Femoston 1/10 mg film-coated tablets PL 46302/0035;
Femoston 2/10 mg film-coated tablets PL 46302/0036.

Basic NHS price: £16.16 (84 tablets).

Legal Category: POM.

Further information is available in the UK from: BGP Products Ltd., Building Q1, Quantum House 60 Norden Road, Maidenhead, Berkshire, SL6 4AY, UK.

Date of Last Revision: 22nd November 2016.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Mylan by phone: 0800 121 8267.

PRESCRIBING INFORMATION:
Femoston-conti 0.5 mg/2.5 mg film-coated tablets
Femoston-conti 1 mg/5 mg film-coated tablets
Refer to the Summary of Product Characteristics for full information.

Presentation: Femoston-conti 0.5 mg/2.5 mg film-coated tablets containing 0.5 mg 17β-estradiol (as hemihydrate) and 2.5 mg dydrogesterone. Femoston-conti 1 mg/5 mg film-coated tablets containing 1 mg 17β-estradiol (as hemihydrate) and 5 mg dydrogesterone.

Indication: Femoston-conti 0.5 mg/2.5 mg and 1 mg/5 mg film film-coated tablets; Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses. Femoston-conti 1 mg/5 mg film-coated tablets: Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

Dosage and Administration: Given as a continuous combined HRT for oral use and every day without interruption. Dosage is one tablet per day for a 28 day cycle. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used. Continuous combined treatment may be started depending on the time since menopause and severity of symptoms. Women experiencing a natural menopause should commence treatment not earlier than at least 12 months after their last natural menstrual bleed. For surgically induced menopause, treatment may start immediately. Can be taken before or after food. Paediatric population: No relevant indication.

Contraindications, Warnings etc: Contraindications: Known breast cancer, known oestrogen-dependent malignant tumours, undiagnosed genital bleeding, untreated endometrial hyperplasia, venous thromboembolism, known thrombophilic disorders, arterial thromboembolic disease, acute liver disease or a history of liver disease, porphyria, known hypersensitivity to the active substances or to any of the excipients.
Warnings: Before initiating or re-instituting HRT, a complete physical and family medical history should be taken. Carefully supervise if leiomyoma or endometriosis, risk factors for thromboembolic disorders, oestrogen-dependent tumours, hypertension, liver disorders, diabetes mellitus, cholelithiasis, migraine or severe headaches, systemic lupus erythematosus, history of endometrial hyperplasia, epilepsy, asthma, otosclerosis and meningioma conditions are present or have previously occurred. Therapy should be discontinued in case a contraindication is discovered; breast cancer, endometrial hyperplasia and carcinoma, ovarian cancer, venous thromboembolism, coronary artery disease, ischaemic stroke, renal dysfunction, hypertriglyceridaemia and in the following situations: jaundice or deterioration in liver function, significant increase in blood pressure, new onset of migraine-type headache, pregnancy. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Oestrogen-progestogen combination treatment is not a contraceptive. Drug Interactions: The metabolism of oestrogens and progestogens may be increased by concomitant use of P450 enzymes such as anticonvulsants and anti-infectives. Ritonavir, nelfinavir and herbal preparations containing St. John’s Wort may induce the metabolism of oestrogens and progestogens. Clinically, an increased metabolism of oestrogens and progestogens may lead to decreased effect and changes in the uterine bleeding profile.

Pregnancy, Lactation and Fertility: Not recommended. If pregnancy occurs withdraw treatment immediately.

Ability to Drive and Operate Machinery: No or negligible influence on the ability to drive and/or to use machines.

Side Effects: Very common: Headache, abdominal pain, back pain, breast pain/tenderness. Common: Vaginal candidiasis, depression, nervousness, migraine, dizziness, nausea, vomiting, abdominal distension (including flatulence), allergic skin reactions (e.g. rash, urticaria, pruritus), menstrual disorders (including postmenopausal spotting, metrorrhagia, menorrhagia, oligo-/amenorrhoea, irregular menstruation, dysmenorrhoea), pelvic pain, cervical discharge, asthenic conditions (asthenia, fatigue, malaise), peripheral oedema, increased weight. Uncommon: Cystitis- like symptoms, increase in size of leiomyoma, hypersensitivity, influence on libido, venous thromboembolism, hypertension, peripheral vascular disease, varicose vein, dyspepsia, abnormal hepatic function occasionally with jaundice, asthenia or malaise, and abdominal pain, gall bladder disorder, breast enlargement, premenstrual syndrome, decreased weight. Rare: Haemolytic anaemia, meningioma, steepening of corneal curvature, contact lenses intolerance, myocardial infarction, stroke, angioedema, vascular purpura, erythema nodosum, chloasma or melasma, which may persist when drug is discontinued, leg cramps. Possible risk factors: Breast cancer, ovarian cancer, endometrial cancer, venous thromboembolism, coronary artery disease and ischaemic stroke. Other adverse reactions: Oestrogen dependent neoplasms both benign and malignant, (e.g. endometrial cancer, ovarian cancer), increase in size of meningioma, systemic lupus erythematosus, hypertriglyceridemia, probable dementia, chorea, exacerbation of epilepsy, arterial thromboembolism, pancreatitis, erythema multiforme, urinary incontinence, fibrocystic breast disease, uterine cervical erosion, aggravated porphyria, thyroid hormones increase.


Name and Address of Marketing Authorisation Holder: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, UK.

PL No: Femoston-conti 0.5 mg/2.5 mg film-coated tablets PL 46302/0037; Femoston-conti 1 mg/5 mg film-coated tablets PL 46302/0038.

Basic NHS price: £24.43 (84 tablets).

Legal Category: POM.

Further information is available in the UK from: BGP Products Ltd., Building Q1, Quantum House 60 Norden Road, Maidenhead, Berkshire, SL6 4AY, UK.

Date of Last Revision: 26th August 2016.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Mylan by phone: 0800 121 8267.

PRESCRIBING INFORMATION:
Zumenon® 1mg Film-coated Tablets
Zumenon® 2mg Film-coated Tablets

Refer to the Summary of Product Characteristics for full information.

Presentation: Zumenon® 1mg film-coated tablets containing 1 mg estradiol (as hemihydrate), Zumenon® 2mg film-coated tablets containing 2 mg estradiol (as hemihydrate).

Indication: Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 6 months since last menses. Zumenon 2mg film-coated tablets should be used for the prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.

Dosage and Administration: Given as a continuous oestrogen only HRT for women with or without a uterus, for oral use and every day without interruption. Dosage is one tablet per day continuously without a break between packs. For initiation and continuation of treatment of postmenopausal symptoms, use the lowest effective dose for the shortest duration. Treatment should be started with Zumenon 1mg. Depending on the clinical response, the dosage can be adjusted to individual need and can be increased by using Zumenon 2mg. In women with a uterus, a progestagen should be added to Zumenon for 12-14 days each month to reduce the risk to the endometrium. Unless there is a previous diagnosis of endometriosis, it is not recommended to add a progestagen in hysterectomised women. In women who are not taking hormone replacement therapy and who are amenorrhoeic, are hysterectomised, or women who switch from a continuous combined hormone replacement therapy, treatment may be started on any convenient day. In women transferring from a cyclic or continuous sequential HRT regimen, treatment should begin the day following completion of the prior regimen. If the patient has regular menstruation periods, treatment is started on day one of bleeding. Can be taken with or without food.

Contraindications, Warnings etc: Contraindications: Known hypersensitivity to the active substances or to any of the excipients, known, past or suspected breast cancer, known or suspected oestrogen-dependent malignant tumours (e.g. endometrial cancer), undiagnosed genital bleeding, untreated endometrial hyperplasia, previous or current venous thromboembolism (deep vein thrombosis, pulmonary embolism), known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency), active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction), acute liver disease or a history of liver disease, porphyria, Non-hysterectomized women without opposing progestogen.
Warnings: Before initiating or re-instituting HRT, a complete physical and family medical history should be taken. Carefully supervise if leiomyoma (uterine fibroids) or endometriosis, risk factors for thromboembolic disorders, oestrogen-dependent tumours (e.g. 1st degree heredity for breast cancer), hypertension, liver disorders, diabetes mellitus, cholelithiasis, migraine or (severe) headache, systemic lupus erythematosus, history of endometrial hyperplasia, epilepsy, asthma, or otosclerosis are present. Therapy should be discontinued in case a contraindication is discovered; jaundice or deterioration in liver function, significant increase in blood pressure, new onset of migraine-type headache, pregnancy. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. If at risk of pregnancy non-hormonal contraceptive methods should be adhered to. Drug Interactions: The metabolism of oestrogens and progestogens may be increased by concomitant use of P450 enzymes such as anticonvulsants (e.g. phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g. rifampicin, rifabutin, nevirapine, efavirenz). Ritonavir, nelfinavir and herbal preparations containing St. John’s Wort may induce the metabolism of oestrogens and progestogens. Clinically, an increased metabolism of oestrogens and progestogens may lead to decreased effect and changes in the uterine bleeding profile. Oestrogens may inhibit CYP450 drug-metabolising enzymes via competitive inhibition such as tacrolimus and cyclosporine A, fentanyl and theophylline. This may lead to a plasma increase of the affected substances up to toxic levels. Careful drug monitoring might be indicated and a dosage decrease of tacrolimus, fentanyl, cyclosporin A, and theophylline may be necessary

Pregnancy and Lactation: Not recommended. If pregnancy occurs withdraw treatment immediately.

Ability to Drive and Operate Machinery: Does not affect the ability to drive or use machines.

Side Effects: Common: Increase and decrease in weight, headache, nausea, abdominal pain, rash, pruritus, leg cramps, metrorrhagia, uterine/vaginal bleeding including spotting, pelvic pain, asthenia. Uncommon: Vaginal candidiasis, hypersensitivity, nervousness, depressed mood, dizziness, visual disturbances, palpitations, venous thromboembolism, hypertension, peripheral vascular disease, varicose vein, dyspepsia, gall bladder disorder, urticaria, erythema nodosum, back pain, change in cervical secretion, menorrhagia, breast pain/tenderness, peripheral oedema, oedema. Rare: Anxiety, increase and decrease in libido, migraine, contact lenses intolerance, bloating, vomiting, hirsutism, acne, muscle cramps, breast enlargement, premenstrual-like symptoms, vaginal discharge, dysmenorrhoea, fatigue. Very rare: Haemolytic anaemia.
Possible risk factors: Breast cancer, ovarian cancer, endometrial cancer, venous thromboembolism, coronary artery disease, ischaemic stroke. Other adverse reactions (frequency unknown): Breast cancer, oestrogen dependent neoplasms benign and malignant, e.g. endometrial cancer, ovarian cancer, increase in size of leiomyoma, probable dementia over the age of 65, chorea, exacerbation of epilepsy, stroke, arterial thromboembolism, i.e. angina and myocardial infarction, venous thromboembolism, i.e. deep leg or pelvic venous thrombosis and pulmonary embolism, pancreatitis (in women with pre-existing hypertriglyceridaemia), gastroesophageal reflux disease, hepatic function abnormal, sometimes with jaundices, angioedema, chloasma, erythema multiforme, vascular purpura, urinary incontinence, fibrocystic breast disease.

Name and Address of Marketing Authorisation Holder: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, UK.

PL No: Zumenon® 1mg Film-coated Tablets PL 46302/0052;
Zumenon® 2mg Film-coated Tablets PL 46302/0053.

Basic NHS price: £6.89 (84 tablets).

Legal Category: POM.

Further information is available in the UK from: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, UK.

Date of Last Revision: 20th July 2018.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Mylan by phone: 0800 121 8267.

References

  1. NICE Guidelines. Menopause: diagnosis and management.
    https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413
  2. Anderson FA, Spencer FA. Circulation 2003; 107(Suppl. 1): 1-9.
  3. De Villiers TJ, et al. Climacteric 2013; 16: 316-337.
  4. Elleste Solo MX80μg Transdermal Patch Summary of Product Characteristics.  
  5. Elleste Solo MX40μg Transdermal Patch Summary of Product Characteristics.
  6. MIMS April 2018. www.mims.co.uk
  7. Elleste Solo 1mg Tablets Summary of Product Characteristics. 
  8. Elleste Solo 2mg Tablets Summary of Product Characteristics. 
  9. Zumenon® 1mg Summary of Product Characteristics. 
  10. Zumenon® 2mg Summary of Product Characteristics.
  11. Mirena® Summary of Product Characteristics.
  12. Utrogestan® Summary of Product Characteristics.
  13. Elleste Duet 1mg Tablets Summary of Product Characteristics. 
  14. Elleste Duet 2mg Tablets, Summary of Product Characteristics.
  15. Schindler AE, et al. Maturitas 2003; 46(Suppl. 1): S7-S16.
  16. Femoston® 1mg/10mg Summary of Product Characteristics. 
  17. Femoston® 2mg/10mg Summary of Product Characteristics.
  18. Elleste Duet Conti Tablets Summary of Product Characteristics.
  19. Femoston® Conti 0.5mg/2.5mg Summary of Product Characteristics. 
  20. Femoston® Conti 1mg/5mg Summary of Product Characteristics.

Terms and Conditions

Terms and Conditions of Purchase 2009

1. Interpretation

In these Conditions, except where a different interpretation is necessary in the context, the parties shall be referred to in the manner set out below and the following expressions shall have the following meanings:

"Mylan"

means Generics UK Limited trading as MYLAN.

"Conditions"

means the terms and conditions of purchase set out in this document together with any special terms and conditions agreed in writing between MYLAN and the Supplier.

"the Contract"

means the Order and the Conditions and any Drawings or other documents which are attached or referred to in the Order or which relate to the Goods ordered.

"Goods"

means the goods or any of them described in the Order including any materials, articles, plant, equipment, products or services or any of them to be supplied to MYLAN pursuant to the Contract.

"Order"

the requirements of MYLAN issued by MYLAN to the Supplier on the official purchase order form of MYLAN to which these Conditions are annexed or otherwise issued by MYLAN in writing to the Supplier;

"Supplier"

the person, firm or company to whom the Order is addressed.

2. Basis of Purchase

  1. The Order constitutes an offer by MYLAN to purchase the Goods subject to the Conditions.
  2. Except in respect of fraudulent misrepresentation, these Conditions alone govern and are incorporated in every contract or other course of dealings made or undertaken by MYLAN with the Supplier. They apply in place of and prevail over any terms or conditions, (whether or not in conflict or inconsistent with these Conditions), contained or referred to in any quotation or other documentation submitted by the Supplier or in correspondence or elsewhere or implied by trade custom, practice or course of dealing unless specifically excluded or varied in writing by a director or other authorised representative of MYLAN and any purported provisions to the contrary are hereby excluded or extinguished and any similar provision in the Supplier’s terms and conditions shall be of no effect.
  3. Any variation of these Conditions is valid only if it is in writing and signed by or on behalf of each of the Supplier and MYLAN. No other action on the part of MYLAN, whether by accepting Goods or otherwise, shall be construed as an acceptance of any other conditions.

3. Ordering Procedure and Orders

  1. MYLAN may place Orders for its requirements of Goods in writing on MYLAN's official purchase order form. The date and place of delivery may be altered by MYLAN from time to time by written notice to the Supplier. The Supplier must not make any changes whatsoever in the colour, specification, design or composition of the Goods once ordered without the prior written consent of MYLAN.
  2. Each Order for Goods by MYLAN from the Supplier is deemed to be an offer by MYLAN to purchase Goods subject to these Conditions and no Order is binding on MYLAN unless and until the Supplier either expressly by giving notice of acceptance, or impliedly by fulfilling the Order, in whole or in part accepts the offer.
  3. The Supplier must immediately inform MYLAN if the Supplier knows or believes that it will not be, or is unlikely to be, able to deliver all or any of the Goods by the date required on the Order and MYLAN is entitled to cancel any Order placed without liability and without prejudice to any other right or remedy.

4. Deliveries

  1. All Goods must be delivered Carriage and Insurance Paid (as that term is defined in Incoterms 2000 Edition) to the address stated on the Order or otherwise notified to MYLAN (“Delivery Address”) except where any provision of these Conditions expressly provides otherwise or unless otherwise agreed in writing. All prices, unless otherwise stated, include packing, crates, packaging and delivery.
  2. The Goods ordered by MYLAN are at the Supplier's risk until delivered to the Delivery Address.
  3. Delivery must be made by the Supplier during MYLAN’s normal working hours (between 8 am and 4 pm Monday to Friday) or as requested by MYLAN. MYLAN accepts no responsibility for Goods delivered outside these times.
  4. The title in the Goods passes to MYLAN on proper delivery to the Delivery Address, whether or not MYLAN has made payment in respect of them, unless payment of the Goods is made prior to delivery, in which case title passes to MYLAN once payment has been made and the Goods have been appropriated to the Contract. The Supplier will indemnify MYLAN against any third party claims regarding title of goods.
  5. Each consignment of Goods ordered by MYLAN must be delivered in full by the due date stipulated by MYLAN and time is the essence of the Agreement. The date for delivery is as specified in the Order, or if no such date is specified then the Supplier shall request a date for delivery from MYLAN and MYLAN will provide such date for delivery to the Supplier. If any Order is only partially fulfilled by the agreed date, then MYLAN reserves the right, without prejudice to any other remedy, either to accept or reject those Goods that have been delivered and, in either case, to cancel the Order in respect of those that have not been delivered on time and to apportion the price accordingly.
  6. All Goods delivered must be accompanied by a despatch note or a consignment note and a packing note quoting the Order reference number (and any relevant part number) which must be displayed prominently. Any indication by MYLAN on delivery that a consignment accords with the consignment note shall not be taken as indicating that MYLAN has accepted the Goods.
  7. MYLAN is entitled to reject any Goods delivered which are not in accordance with the Contract within 60 days of the defect coming to its attention.
  8. The Supplier bears the risk in respect of any rejected Goods. MYLAN is entitled to charge the Supplier a daily storage charge for the period in which any rejected Goods remain uncollected.
  9. If the Supplier fails to deliver the Goods ordered by MYLAN in full or in part or to make delivery within the period specified, then the Supplier is liable to indemnify and reimburse MYLAN fully for its loss or damage directly or indirectly attributable to the delay in delivery or failure to deliver, including (without limitation) any expenditure reasonably incurred by MYLAN which are in any way attributable to the Supplier's failure to deliver the Goods on the due date.

5. The Goods

  1. The Supplier warrants, represents and undertakes to MYLAN that the Goods delivered or supplied:
    1. will comply with the Contract and/or any specifications issued in connection therewith in quantity, quality and description for the Supplier's guarantee period whichever is the longer;
    2. will be of satisfactory quality and fit for any purpose for which they are supplied and held out by the Supplier and for which they are commonly used;
    3. will be free from defects in design, material and workmanship;
    4. will conform with all relevant legal and statutory requirements including, but without limitation, the Trades Descriptions Act 1968, the Health and Safety at Work Act 1974, the Consumer Safety Act 1978, the Sale and Supply of Goods Act 1994, the Weights and Measures Act 1985, the Consumer Protection Act 1987 and any amendments, modifications, re-enactments and regulations made under any of those acts;
    5. will be in accordance with the latest current issue of any relevant British Standards, Specifications and Codes of Practice, as at the date of the Order and of delivery or supply unless agreed otherwise in writing.

The warranties set out in this Condition 5.1 will continue in force notwithstanding the acceptance or use by the Company of the Goods.

  1. Without prejudice to any other remedy, if any Goods are not supplied in accordance with the Contract then MYLAN is entitled:
    1. to require the Supplier to supply replacement Goods in accordance with the Contract within 7 days; or
    2. at MYLAN's sole option, and whether or not MYLAN has previously required the Supplier to supply any replacement Goods, to treat the Contract as discharged by the Supplier's breach and require the repayment of any part of the price which has been paid and any sums due pursuant to Condition 5.3.
  2. The Supplier must indemnify MYLAN in full against all direct, indirect or consequential liability, loss, (including loss of profits or business) damages, costs and expenses (including legal expenses) awarded against or incurred or paid by MYLAN as a result or in connection with:
    1. a breach of any warranty given by the Supplier in relation to the Goods or warranty or term of the Contract;
    2. any claim that the Goods or their importation, use or resale, infringes the patent, copyright, design right, trade mark or other intellectual property rights of any other person;
    3. any claim arising from injury to person (except where solely caused by MYLAN's negligence) or damage to property arising from the use of the Goods or the fulfilment of the Contract or sustained by the Supplier, its employees or agents while on MYLAN's premises.
  3. The Company's rights under these Conditions are in addition to the statutory conditions implied in favour of MYLAN by the Sale of Goods Act 1979.

6. Price

  1. The price of the Goods will be as stated in the Order and, unless otherwise stated is:
    1. exclusive of any applicable value added tax (which shall be payable by MYLAN subject to receipt of a VAT Invoice); and
    2. inclusive of all charges for packaging, package, carriage, insurance and delivery of the Goods to the Delivery Address and any duties, taxes or levies other than Value Added Tax.
  2. No increase in the price may be made, whether on account of increased material, labour or transport costs or otherwise, without the prior written consent of MYLAN in writing.
  3. The Company is entitled to the benefit of any discount for prompt payment, bulk purchase or volume of purchase customarily granted by the Supplier, whether or not shown on its own terms and conditions of sale.

7. Payment

  1. The Supplier may invoice MYLAN on or at any time after proper delivery of the Goods and each invoice must quote the order reference number (and any part number) accompanied by a full detailed statement.
  2. Unless otherwise stated in the Order, MYLAN will pay the price of the Goods within 60 days from the last day of the month in which the invoice is issued pursuant to Condition 7.1 but time for payment is not of the essence.
  3. Without prejudice to any other right or remedy, MYLAN is entitled to set off against the price of the Goods any sums owed to MYLAN by the Supplier.
  4. If MYLAN fails to pay the price of the Goods within 60 days from the last day of the month in which the invoice is issued, in accordance with Condition 7.2, other than in the case of a bona fide dispute, MYLAN shall pay interest on the overdue sum for the period from and including the date of the invoice up to the date of actual payment in accordance with clause 7.5.
  5. The interest referred to in clause 7.4 shall be paid at the rate of 4% above the base rate from time to time of Barclays Bank plc.

8. Termination

  1. Notwithstanding MYLAN's right to cancel the Order for cause as referred to elsewhere in these Conditions (in which case MYLAN shall have no liability) MYLAN is entitled by written notice to cancel the Order at its convenience without fault on the part of the Supplier in respect of all or part only of the Goods by giving notice to the Supplier at any time prior to delivery or performance, in which event MYLAN's sole liability is to pay to the Supplier the lesser of:
    1. the price for the Goods in respect of which MYLAN has exercised its right of cancellation, less the Supplier's net saving of cost arising from cancellation; and
    2. the reasonable costs of production to the Supplier of the Goods in respect of which MYLAN has exercised its right of cancellation from the date of the Order to the date of cancellation where the Goods (or any materials comprised within them) cannot reasonably be used by the Supplier itself or for any other customers, less the price of the Goods which will or can be expected to be obtained by the Supplier on the ultimate sale of such Goods.
    MYLAN will not be liable to the Supplier for any loss of anticipated profits or any consequential loss.
  2. MYLAN is entitled to terminate the Contract with immediate effect by written notice if the Supplier becomes unable to pay its debts as they fall due, or the value of its assets is less than the amount of its liabilities taking into account its contingent and prospective liabilities; or a statutory demand is served, a receiver is appointed or any insolvency procedure under the Insolvency Act 1986 is instituted or occurs; or if the Supplier commits a material breach of the Contract or any other contract between MYLAN and the Supplier.
  3. If any of the events described in Condition 8.2 occurs MYLAN is entitled without prejudice to any of its other rights to avail itself of any one or more of the following remedies at its discretion, whether or not any part of the Goods have been accepted by MYLAN:
    1. to rescind the Order;
    2. to reject the Goods (in whole or in part) and return them to the Supplier at the risk and cost of the Supplier on the basis that a full refund for the Goods so returned will be paid immediately by the Supplier;
    3. at MYLAN's option to give the Supplier the opportunity at the Supplier's expense either to remedy any defect in the Goods or to supply replacement Goods and carry out any other necessary work to ensure that the terms of the Contract are fulfilled;
    4. to refuse to accept any further deliveries of the Goods but without any liability to the Supplier;
    5. to carry out at the Supplier's expense any work necessary to make the Goods comply with the Contract; and
    6. to claim such damages as may have been sustained in consequence of the Supplier's breach or breaches of the Contract.
  4. All provisions of this Agreement which in order to give effect to their meaning need to survive the termination of the Agreement in whole or in part will remain in full force and effect after such termination.

9. Ownership of property

  1. All Drawings, dies, moulds, tooling and other proprietary information (including without limitation know-how, specifications, inventions, processes or initiatives) ("Information") either furnished by MYLAN to the Supplier or created or provided by the Supplier for the purpose of the Contract must remain the property of MYLAN and the Supplier must treat such Information as strictly confidential, must keep it safely and must not use nor disclose it except as strictly required in the course of performance of the Contract.
  2. Unless MYLAN has otherwise agreed in writing, all Information prepared by the Supplier in connection with the Contract will be MYLAN's sole property and MYLAN may reproduce and use such Information freely for any purposes whatsoever.

10. General

  1. Any communication to be given in connection with this Contract must be in writing in English and must (unless otherwise set out in this Condition) either be delivered by hand or sent by [first class/registered or recorded] post (airmail if to an address outside the United Kingdom) or fax to the address of the relevant party. For the purposes of clauses 3.1 and 8.1, the Company shall be entitled to deliver communications by email to the email address provided by the Supplier.
  2. In the absence of evidence of earlier receipt, a communication sent according to this Condition will be deemed to have been received:
    1. if delivered by hand, at the time of delivery; or
    2. if sent by first class post, on the second day after posting; or
    3. if sent by airmail, on the sixth day after posting; or
    4. if sent by fax, at the time of completion of transmission by the sender.
    If, under the preceding provisions of this Condition, a communication would otherwise be deemed to have been received outside normal business hours in the place of receipt, being 9:30am to 5:30pm on a day other than a Saturday, Sunday or public holiday in England and Wales ("Business Day"), it shall be deemed to have been received at 9:30am on the next Business Day.
  3. A waiver of any right or remedy must be in writing and signed by the grantor. An omission to exercise or delay in exercising any right or remedy shall not constitute a waiver of that right or remedy. No waiver by MYLAN of any right or remedy shall constitute a continuing waiver of that right or remedy or a waiver of any other right or remedy and no action by MYLAN in respect of any breach will be deemed to bind MYLAN to take the same action in respect of future breaches.
  4. The Company may, but the Supplier may not, without the prior written consent of MYLAN:
    1. assign any of its rights under these Conditions; or
    2. transfer any of its obligations under these Conditions; or
    3. sub-contract or delegate any of its obligations under these Conditions; or
    4. charge or deal in any other manner with these Conditions or any of its rights or obligations.
    Any purported assignment, transfer sub-contracting, delegation, charging or dealing in contravention of this Condition 10.4 shall be ineffective. These Conditions are personal to the Buyer and are entered into by the Buyer for its own benefit and not for the benefit of another third person or party.
  5. If any provision of these Conditions is held to be invalid or unenforceable by any judicial or other competent authority, all other provisions of these Conditions will remain in full force and effect and will not in any way be impaired. If any provision of these Conditions is held to be invalid or unenforceable but would be valid or enforceable if some part of the provision were deleted, or the period of the obligation reduced in time or the range of activities or area covered reduced in scope the provision in question will apply with the minimum modifications necessary to make it valid and enforceable.
  6. The Supplier must not without the prior written permission of MYLAN advertise or announce that it supplies Goods to MYLAN and shall discontinue any such permitted advertisement or announcement on demand.
  7. The Supplier will at all times insure and keep itself insured with a reputable insurance company against all insurable liability under the Contract or in respect of the Goods and shall produce on request by MYLAN the policy of such insurance and the premium receipts.

11. Interpretation

  1. The clause headings used in these Conditions are inserted for ease of reference only and do not affect construction.
  2. References to "writing" or "written" includes any other non-transitory form of visible reproduction of words.
  3. References to persons include bodies corporate, unincorporated associations and partnerships, in each case whether or not having a separate legal personality.
  4. References to the word "include" or "including" (or any similar term) are not to be construed as implying any limitation and general words introduced by the word "other" (or any similar term) will not be given a restrictive meaning by reason of the fact that they are preceded by words indicating a particular class of acts, matters or things and all definitions in clause 1.1 will apply, where the context requires, to cognate forms and plural and singular forms, and any other forms.
  5. Except where the context specifically requires otherwise, words importing one gender will be treated as importing any gender, words importing individuals will be treated as importing corporations and vice versa, words importing the singular will be treated as importing the plural and vice versa, and words importing the whole will be treated as including a reference to any part thereof.
  6. References to statutory provisions, enactments or EC Directives will include references to any amendment, modification, extension, consolidation, replacement or re-enactment of any such provision, enactment or Directive (whether before or after the date of this Agreement), to any previous enactment which has been replaced or amended and to any regulation, instrument or order or other subordinate legislation made under such provision, enactment or Directive.

12. Governing Law and Jurisdiction

The Contract is governed by and is to be construed in accordance with English law. The parties irrevocably agree that the courts of England and Wales will have exclusive jurisdiction to settle any dispute, which may arise out of or in connection with the Contract.

Privacy policy

Generics (UK) Limited trading as Mylan (the “Company”) is committed to protecting and respecting your privacy. This is the privacy policy of the Company. If you feel that the Company is not abiding by this privacy policy, you should immediately contact enquiry@mylan.co.uk by email and we will try to resolve your concerns.

This policy sets out the basis on which any personal data the Company collects from you, or that you provide to us, will be processed by us. Please read the following carefully to understand our views and practices regarding your personal data and how the Company will treat it.

For the purpose of the Data Protection Act 1998 (the Act), the data controller is Generics (UK) Limited of Station Close, Potters Bar, Hertfordshire EN6 1TL.

This privacy policy complies with all applicable privacy legislation.

For the purposes of this policy, personal data has the same meaning as personal information, which is information about an identifiable individual.

What information may we collect from you?

We may collect, store and process the following data about you:

  1. details of your visits to our site www.mylan.co.uk (the “Website”) including, but not limited to, traffic data, location data and other communication data, and information about your computer;
  2. information that you provide to us for the purpose of registering to use the Website, subscribing to the Company’s service, posting material, requesting further services and/or applying for a position of employment with us (including but not limited to your name, address, telephone number and e-mail address);
  3. information that you provide to us by completing any other forms on our website or if you contact us with comments or specific requests (including but not limited to your name, address, telephone number and e-mail address). The Company may also ask you for information when you report a problem with the Website;
  4. if you contact the Company, it may keep a record of that correspondence;
  5. the Company may also ask you to complete surveys that it uses for research purposes, although you do not have to respond to them.

IP addresses and cookies

The Company may collect information about your computer, including where available your IP address, operating system and browser type, for system administration. This is statistical data about our users' browsing actions and patterns, and does not identify any individual. To the extent that any of this information can be considered personal information, it is used solely for the purposes of administering our Website, and is not disclosed for any other purpose, except as described on this Website.

Please refer to the following page for our full cookie policy.

What do we use your personal information for?

The Company may use information held about you in the following ways:

  1. for administration of this Website;
  2. for statistical purposes to help improve this Website;
  3. to provide you with information that you request from the Company or which the Company feels may interest you, where you have consented to be contacted for such purposes;
  4. to deal with enquiries and/or applications made by you through the related forms available on the Website;
  5. to ensure that content from the Website is presented in the most effective manner for you and for your computer;
  6. to carry out our obligations arising from any contracts entered into between you and us;
  7. to allow you to participate in interactive features of our service, when you choose to do so;
  8. to notify you about changes to our service.

Disclosures

The Company will not sell, share transfer or rent the information collected from this Website, except as provided below.

We may disclose your personal information to any member of our group, which means our subsidiaries, our ultimate holding company and its subsidiaries, as defined in section 1159 of the UK Companies Act 2006.

The Company may disclose your personal information to third parties:

  1. in the event that the Company sells or buys any business or assets, in which case the Company may disclose your personal data to the prospective seller or buyer of such business or assets;
  2. if the Company or substantially all of its assets are acquired by a third party, in which case personal data held by it about its customers will be one of the transferred assets;
  3. to the extent required by the rules of any listing authority or stock exchange on which the shares of the Company or any member of its group are listed or traded;
  4. if the Company is under a duty to disclose or share your personal data in order to comply with any legal obligation, or in order to enforce or apply our terms and conditions of use and other agreements; or to protect the rights, property, or safety of the Company, our customers, or others. This includes exchanging information with other companies and organisations for the purposes of fraud protection and credit risk reduction.

Security of your personal data

Unfortunately, the transmission of information via the internet is not completely secure. The Company will do its best to protect your personal data, but cannot guarantee the security of your data transmitted to the Website; any transmission is at your own risk. Once the Company has received your information, it will use strict procedures and security features to try to prevent unauthorised access.

International data transfers

To offer our services, we may need to transfer your Personal Data to countries other than the country in which the data was originally collected, including the United Sates, where we are headquartered.  Those countries may not have the same data protection laws as the country in which you initially provided that information. When we transfer your Personal Data to other countries outside the European Economic Area ("EEA"), we will protect it as described in this Privacy Policy in compliance with applicable legal requirements, such as the EU-U.S. Privacy Shield Framework, providing adequate protection for the transfer of Personal Data to countries outside of the EEA. By providing Personal Data to us, you consent to the transfer of Personal Data to countries outside of your country of residence, including the U.S. For more information about the Privacy Shield or see our certification, please see Privacy Shield.

To see a copy of our Website Privacy Shield Policy, please click here.

Changes to this Policy

We may update this privacy policy from time-to-time by posting a new version on our website. This Privacy Policy was last updated in June 2017.

Information requests and changes

You can ask for a copy of the information we hold about you at any time. Provision of such information is not currently subject to the payment of a fee. We will also correct or update any inaccuracies in your information at your request.

Third party websites

From time to time we may provide links to the websites of other organisations, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them.

Contact

If you have any queries concerning your personal information or any questions on our use of the information, please contact dataprivacy@mylan.com.

Mylan's HRT Treatment Navigator

Group photo

Is her uterus intact?

Group photo
Elleste logo
Femoston logo
Femoston conti logo
Zumenon logo

Here is an example of the output that will be provided once
you have answered a few quick questions. Your answers will be
summarised and the most appropriate Mylan treatment option will
be displayed with explanations.

The Mylan HRT Treatment Navigator is intended to aid and not to
replace clinical decision making.

Treatment Navigator Preview Mobile
Treatment Navigator Previe Desktop

HCP Disclaimer

This website is intended for healthcare professionals only.